Literature DB >> 16622680

Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy.

Rosa Méndez1, Francisco Ruiz-Cabello, Teresa Rodríguez, Ana Del Campo, Annette Paschen, Dirk Schadendorf, Federico Garrido.   

Abstract

The cytotoxic activity of T cells selects the outgrowth of tumor cells that escape from immune surveillance by different strategies. The different mechanisms that interfere with immune recognition and limit vaccination efficiency are still poorly understood. We analysed six cell lines established from different metastases of melanoma patient UKRV-Mel-20 for specific characteristics known to have an impact on the tumor-T cell interaction: (1) alterations in the HLA class I phenotype, (2) expression of Fas/CD95, and (3) expression of specific cytokines and chemokines. One of the cell lines, UKRV-Mel-20f, exhibited an HLA class I haplotype loss and just this cell line was also characterised by the expression of Fas/CD95 and of relatively high levels of proinflammatory chemokines suggesting that the cytotoxic activity of tumor-infiltrating T cells might have selected the outgrowth of this tumor cell variant. All other cell lines analysed showed no alterations in HLA class I expression, but, in contrast to UKRV-Mel-20f, expressed much lower levels of Fas/CD95 and of proinflammatory chemokines and some of them produced high levels of immunosuppressive TGF-beta1. These results suggest that in patient UKRV-Mel-20, tumor cells interfere with T cell recognition by different strategies which might partially explain why this patient did not have a clinical response to an autologous tumor cell vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622680     DOI: 10.1007/s00262-006-0166-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

1.  Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.

Authors:  Midori Isobe; Shingo Eikawa; Akiko Uenaka; Yoichi Nakamura; Tetsuo Kanda; Shigeru Kohno; Kiyotaka Kuzushima; Eiichi Nakayama
Journal:  Cancer Immun       Date:  2009-10-01

Review 2.  Influence of immune privilege on ocular tumor development.

Authors:  Kyle C McKenna; Peter W Chen
Journal:  Ocul Immunol Inflamm       Date:  2010-04       Impact factor: 3.070

Review 3.  Clinical utilization of chemokines to combat cancer: the double-edged sword.

Authors:  Chiara Dell'Agnola; Arya Biragyn
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

4.  Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors.

Authors:  Isabel Maleno; Natalia Aptsiauri; Teresa Cabrera; Aurelia Gallego; Annette Paschen; Miguel Angel López-Nevot; Federico Garrido
Journal:  Immunogenetics       Date:  2010-11-18       Impact factor: 2.846

Review 5.  Antigen-specific vaccines for cancer treatment.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design.

Authors:  Maciej Kmieciak; Johanna K Morales; Joshua Morales; Elizabeth Bolesta; Margaret Grimes; Masoud H Manjili
Journal:  Cancer Immunol Immunother       Date:  2008-02-16       Impact factor: 6.968

Review 7.  Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer.

Authors:  Kosei Yasumoto; Takeshi Hanagiri; Mitsuhiro Takenoyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-09-13

8.  Effect of cytokine-induced killer cells on immune function in patients with lung cancer.

Authors:  Yanyan Pan; Yuanyuan Wu; Jun Ji; Hongjiao Cai; Heshuang Wang; Yifan Jiang; Limin Sang; Jin Yang; Yanyan Gao; Ying Liu; Liangwei Yin; L I Zhang
Journal:  Oncol Lett       Date:  2016-02-29       Impact factor: 2.967

9.  Genetic evolution of T-cell resistance in the course of melanoma progression.

Authors:  Antje Sucker; Fang Zhao; Birgit Real; Christina Heeke; Nicola Bielefeld; Stefan Maβen; Susanne Horn; Iris Moll; Raffaela Maltaner; Peter A Horn; Bastian Schilling; Francesco Sabbatino; Volker Lennerz; Matthias Kloor; Soldano Ferrone; Dirk Schadendorf; Christine S Falk; Klaus Griewank; Annette Paschen
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

Review 10.  Therapeutic cancer vaccines: past, present, and future.

Authors:  Chunqing Guo; Masoud H Manjili; John R Subjeck; Devanand Sarkar; Paul B Fisher; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.